Latest news with #DavidMoore
Irish Times
16 hours ago
- General
- Irish Times
I have mistletoe in my garden. Will it kill the host tree?
I have mistletoe in a tree in my garden. I was told to keep it as it's so unusual, but I'm afraid it might kill the host tree. Can you advise me? S Doyle, Co Dublin Relatively rare in Ireland, mistletoe (Viscum album, or 'drualas' as it's known as Gaeilge) is a hemiparasitic, non-native, shrubby evergreen species that depends on a host plant – typically a large, established, deciduous tree – to survive. In the National Botanic Gardens in Glasnevin, where it was possibly deliberately introduced by the then curator of the gardens, Dr David Moore, in the Victorian era, this wildlife-friendly plant can be found growing on apple trees, birch, maples, robinias, davidias, limes, crataegus, sorbus and poplars. Its seed is typically spread by birds, which is why mistletoe is also increasingly found growing in private gardens close to the National Botanic Gardens. But despite its undoubted charm and ancient history of use (Virgil mentions it in the Aeneid), you're right to be somewhat concerned about the potential damage it might cause. [ Why is our holly bush suddenly shedding? Opens in new window ] Although it's relatively slow-growing, a large, well-established colony of mistletoe can stress the host plant, on which it is dependent as a source of water. This is particularly true during periods of drought, when the host tree is already under pressure and fighting to reduce water loss through transpiration and evaporation. As a result it's not unusual to see the latter showing signs of wilting during a prolonged dry spell. Mistletoe can also cause distortion and swelling of branches, gradually making host trees unstable. For this reason colonies in the National Botanic Gardens are very carefully managed and any potential damage is minimised by them being systematically harvested every couple of years to reduce their weight and spread. READ MORE Unless you're prepared to similarly manage its growth, regrettably the safest choice is to cut the mistletoe out of your host tree. But removing it from your garden may be tricky, especially if it has established itself high up in branches where it's difficult to reach. There is, of course, the chance that it might re-establish itself, so you'll also need to keep a watchful eye out in the years to come.
CBS News
2 days ago
- Sport
- CBS News
History behind Oakmont Country Club ahead of U.S. Open
The story of golf could not be told without the Oakmont Country Club. For a record-setting 10th time, the golf course is hosting the U.S. Open. It's challenged the best in the world for more than 100 years and will host this year's U.S. Open from June 12-15. "The best of the best tend to win here, and sometimes the best of the best have their hearts broken here," Oakmont Country Club historian David Moore said. Since 1903, the Oakmont Country Club has rewarded the perfect shot and punished mistakes. Arguably, one of the toughest spots is the iconic church pews. According to Moore, they've changed names and designs. They got their name during the 1960s from a newspaper writer. "When he said if you hit it into these church pew-like bunkers, only divine intervention can help you save par, and the name has stuck ever since," Moore said at the Oakmont Country Club. As for the name of the club, it can be a bit misleading. More than 90% of it is in Plum Borough. "Oakmont was named after the town in which the train station was in, and that's why it's not Plum Country Club," Moore said. However, its place in golf history can't be questioned. It has hosted the U.S. Open more than any other course, with its first one in 1927. The club has hosted one every decade, except the 1940s, since then. "Between Johnny Miller's 63, Jack [Nicklaus] and [Arnold Palmer] in '62 and Ben Hogan's fourth and final victory in 1953," Moore said. From winning birdies to missed putts and clutch drives, hole 18 may have created the most emotional history. "Eighteen has just been instrumental in crowning or breaking hearts over the last 120 years here," Moore said. Next week, a new chapter will be written.
Sky News
24-05-2025
- Sky News
Police officer 'fighting for his life' after incident while on duty in Buckinghamshire
A police officer is in a life-threatening condition in hospital after being seriously injured in a road traffic incident while on duty, Thames Valley Police has said. The incident took place in Stoke Poges, Buckinghamshire, at about 10.20 pm on Thursday. Two men from Slough, aged 28 and 38, have been arrested on suspicion of attempted murder and causing serious injury by dangerous driving. A 43-year-old man, also from Slough, has been arrested on suspicion of assisting an offender and perverting the course of justice. Allen Horn, a 56-year-old local postman, said neighbours had heard a car, "but nobody saw anything as far as I know". He added: "I came out in the morning, and the road is closed." Matthew Barber, police and crime commissioner for Thames Valley, said: "My thoughts are with the officer, his family and his colleagues who will also be deeply affected. "It is another stark reminder of the dangers that our police and emergency service colleagues face on a daily basis." David Moore, Conservative councillor for Farnhams and Stoke Poges, said: "I am deeply shocked and saddened to learn that one of our brave police officers is fighting for his life following this horrific incident. "My thoughts and prayers are with him and his loved ones at this incredibly difficult time, and I wish him a full and swift recovery."
Yahoo
22-05-2025
- Yahoo
Deputies seeking suspect in robbery of Onslow County convenience store
HUBERT, N.C. (WNCT) — Deputies with the Onslow County Sheriff's Office are investigating a robbery at a convenience store in Hubert early Wednesday, May 21, 2025. It happened around 4:30 a.m. at the Beast Mart Gas Station and Convenience Store on Sand Ridge Road. Upon arriving, deputies found someone had taken an unknown amount of cash from the register. The suspect had left the store by that time and deputies searched the area but were not able to find the suspect. Detectives are trying to identify the suspect. Anyone with information is asked to contact Det. David Moore at 910-989-4040. Crime Stoppers offers a cash reward of up to $5,000 for information deemed valuable to law enforcement. Information can also be shared anonymously via Text-A-Tip by typing TIP4CSJAX and your message to 274637 (CRIMES). Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
08-05-2025
- Business
- Yahoo
Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Sales Growth: 18% in the first three months of 2025. Operating Profit Growth: 20% in the first three months of 2025. US Operations Sales Growth: 17% in the first three months of 2025. International Operations Sales Growth: 19% in the first three months of 2025. GLP-1 Diabetes Sales Growth: 11%, with US operations growing 10% and International Operations growing 13%. Obesity Care Sales Growth: 65%, with US operations growing 40% and International Operations growing 137%. Rare Disease Sales Growth: 3%, with International Operations growing 5% and US operations growing 1%. Gross Margin: Decreased to 83.5% from 84.8% in the first three months of 2024. Net Profit Increase: 14% in the first three months of 2025. Diluted Earnings Per Share: Increased by 15% to DKK6.53. Free Cash Flow: DKK9.5 billion compared to DKK5 billion in the first three months of 2024. Capital Expenditure: DKK13.4 billion compared to DKK8.4 billion in 2024. Return to Shareholders: DKK36.7 billion, mainly as dividends in the first three months of 2025. Warning! GuruFocus has detected 1 Warning Sign with NVO. Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Novo Nordisk AS (NYSE:NVO) reported an 18% sales growth and 20% operating profit growth in the first quarter of 2025. The company is serving nearly 46 million patients with diabetes and obesity treatments, an increase of almost 4 million from the previous year. Novo Nordisk AS (NYSE:NVO) completed the pivotal trial REDEFINE 2 for its next-generation obesity treatment, CagriSema, and remains on track for submission in early 2026. The US FDA accepted the application for Wegovy 2.4 mg for treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review. Novo Nordisk AS (NYSE:NVO) has expanded its presence in the US with over 10,000 full-time employees and significant investments in manufacturing sites. Total carbon emissions increased by 37% due to the acquisition of new production sites and capital expenditure activities. The company reduced its full-year outlook due to lower-than-planned branded GLP-1 penetration, impacted by the rapid expansion of compounding in the US. Novo Nordisk AS (NYSE:NVO) faces challenges with unlawful compounding of semaglutide in the US, affecting the uptake of Wegovy prescriptions. The gross margin decreased to 83.5% from 84.8% in the first quarter of 2024, mainly due to amortizations and depreciations related to Catalent. Net financial items showed a net loss of DKK1.8 billion, primarily reflecting losses on hedge currencies and financing costs related to the Catalent transaction. Q: How does Novo Nordisk plan to address the issue of compounding in the US, especially with partnerships like HIMSS? A: David Moore, Executive Vice President, US Operations, stated that Novo Nordisk does not support unlawful compounding and is against illegal importation and continuation of compounding in the US. The company has collaborated with telehealth providers to ensure patients have access to legitimate Wegovy through Novocare Pharmacy. They expect the FDA to enforce the law against unlawful compounding by May 22. Q: What are the expectations for Ozempic growth in International Operations once supply constraints are removed? A: Maziar Doustdar, Executive Vice President, International Operations, explained that Ozempic has been launched in 80 markets and is expected to see accelerated growth as supply constraints are lifted. The company has a 64% volume market share on injectable GLP-1s and plans to continue promoting Ozempic aggressively. Q: Can you provide more details on the impact of compounding on Wegovy market share and the guidance for the second half of the year? A: Karsten Munk Knudsen, Chief Financial Officer, noted that the guidance assumes a significant number of patients on compounded products will switch to branded products in the second half of the year. The company expects to capture patients transitioning from compounded semaglutide to branded Wegovy, supported by cash offerings and telehealth collaborations. Q: How does Novo Nordisk view the competitive landscape with Mounjaro and the potential for Ozempic growth? A: David Moore highlighted that the GLP-1 class continues to grow, and Novo Nordisk is focused on leveraging the broad label of Ozempic. The company has launched a new campaign, "Ozempic Era," to emphasize the benefits of the product and aims to maintain patient retention and increase dosage adherence. Q: What is the outlook for oral semaglutide 25-milligram, and how does Novo Nordisk plan to compete in the oral GLP-1 market? A: Lars Fruergaard Joergensen, CEO, stated that Novo Nordisk is well-positioned to launch oral semaglutide 25-milligram, assuming positive regulatory outcomes. The company believes the oral segment will be smaller than injectables but is confident in competing effectively with a known molecule that offers convenience and efficacy similar to Wegovy. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
